MaxCyte (MXCT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte Inc., a leader in cell-engineering technologies, has issued 128,480 new shares of common stock, bringing the total issued stock capital to 105,298,880 shares as of September 30, 2024. This move, part of the company’s block admission facility, aids shareholders in determining their interest notifications. MaxCyte continues to innovate in the cell therapy market with its ExPERT platform, aiming to advance the development of cell-based therapeutics.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.